Rezolute completes enrollment of its phase 2 study in diabetic macular edema (“dme”)

Redwood city, calif., dec. 13, 2023 (globe newswire) -- rezolute, inc. (nasdaq: rzlt), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the completion of enrollment in its rz402 phase 2 study in diabetic macular edema (“dme”).
RZLT Ratings Summary
RZLT Quant Ranking